With the high cost of bringing a new drug to market, pharmaceutical companies need to zero in quickly on which drugs show the best potential for medical results and growth. Therefore, companies are increasingly making the effort to identify these drugs earlier in the development process, by better understanding and targeting patient populations. This requires aggregating and analyzing data from a number of internal and external medical, economic, and social sources.
WNS has positioned itself for research and analytics expertise to support drug development and commercial services activities with a scope of services to understand and address a targeted patient population by therapeutic and geographic area, and the competitive positioning of the pharma company. Its recent acquisition of Value Edge Services brings in complementary leadership, talent, and tools.
In our recent HfS Blueprint on Pharma BPO for R&D and Commercial Services, we noted that while WNS has a proven model for integrating with client research and analytics teams at pharmaceutical companies, it is in early stages of developing tools and a broader talent base. This acquisition addresses these areas by adding:
In our recent study, WNS received high marks for being collaborative, and integrating people and skills into client organizations. We did note, however, a lack of tools and use of its own technology to drive results. It’s also a model that can be difficult to scale, given the reliance on analytics and subject matter expertise to be effective. This $17.5 million acquisition shows WNS is focused on addressing these shortcomings. The acquired leadership, tools, and skills add depth and breadth to help WNS partner with life sciences companies better use their data to achieve the end goal—to help identify and manage “which drugs will be most applicable and relevant to the target population and will be bought.”
The challenge ahead is to invest in automation and talent development to ensure that it can scale the joint capability post acquisition. HfS believes WNS has an opportunity here to focus its model on a unique value proposition—a center of excellence that brokers capability across their own and client organizations, and works across the drug development and commercial services business units in client companies.
If there is one lesson we will eventually take from COVID-19, it’s the paranoia that government and business leaders now live with: the constant fear that a crisis like this could ever catch them cold again. This paranoia must spur...
Migrating to cloud applications can achieve speed, flexibility, and ease of management of IT environments. However, it can also be a mammoth undertaking technically and organizationally. A merger, acquisition, divestiture, or end of life of a legacy system presents an...